# Xiaolin Xu

> Xiaolin Xu is a Series D investor at Huagai Capital backing Biotechnology and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Huagai Capital](https://shizune.co/investors/profile/huagai-capital)
- Location: Beijing, China
- Total investments: 3
- Last investment: Mar 2025
- Lead investor: 100%
- Last updated: Aug 2026

Xiaolin Xu is a Series D investor at Huagai Capital in Beijing focused on Biotechnology and Health Care. Xu Xiaolin is the Chairman and co-founder of Huagai Capital. Before this, he was the General Manager of CCB International Wealth Management Co., Ltd. (CCBI), and the Director and Chief Investment Officer of CCB International Asset Management. Prior to joining CCB International, he was the General Manager of M & A Department of Great WallSecurities. He is currently the first Executive Chairman of China, China Venture Capital Committee of China Venture Capital Association students, "China Health Care Investment Forum 50" sponsors.Xu obtained his BA in International Economics and EMBA from Peking University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Health Care | 2 | 67% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |
| Medical Device | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 1 | 33% |
| Series G | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| China | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Shanghai Bioshine Biotechnology Co. | Shanghai Bioshine Biotechnology Co. is a bitotech company offering biopharmaceutical, medical research, and in vitro diagnostic solutions. |  | Venture - Series Unknown | Mar 04, 2025 |  |
| Synaptic Medical | Synaptic Medical is a medical device company focused on developing and commercializing breakthrough products for the treatment of cardiac arrhythmias and other cardiovascular diseases. Their mission is to develop unique, cost-effective, and clinically advanced technologies with the highest quality to enable physicians to optimize and expandtreatment options. The company was founded in 2005 in Minnesota. | $60M | Series G | Mar 25, 2021 |  |
| MicuRx Pharmaceuticals | MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available inChina. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China. | $42.5M | Series D | Aug 05, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together
- [SIG China (SIG Asia Investments)](https://shizune.co/investors/profile/sig-china) — VC Fund, 1 deal together
- [Sinopharm-CICC](https://shizune.co/investors/profile/sinopharm-cicc) — VC Fund, 1 deal together
- [Zero2IPO](https://shizune.co/investors/profile/zero2ipo) — VC Fund, 1 deal together

## About Huagai Capital

VC Fund · Beijing, China

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

5 contacts available at Huagai Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Lu Binghui | President & Co-Founder | https://shizune.co/investors/profile/lu-binghui |
| Meng Nan | Executive General Manager | https://shizune.co/investors/profile/meng-nan-d449 |
| Wang Shaokun | Vice President | https://shizune.co/investors/profile/wang-shaokun |
| Xiaolin Xu | Chairman & Co-founder | https://shizune.co/investors/profile/xiaolin-xu |
| Zeng Zhiqiang | Managing Partner | https://shizune.co/investors/profile/zeng-zhiqiang |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Xiaolin Xu invest in?

Xiaolin Xu invests primarily in Biotechnology, Health Care and Medical startups, most often at Series D and Series G stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Xiaolin Xu last invest?

The most recent investment recorded for Xiaolin Xu closed in Mar 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co